7.54 
0.08(1.05%) Jun 18, 4:02PM EDT
| Prev Close: | 7.62 |
|---|
| Open: | 7.60 |
|---|
| Bid: | 0.00 x 1000 |
|---|
| Ask: | 8.20 x 500 |
|---|
| 1y Target Est: | 9.06 |
|---|
| Beta: | 0.69 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 7.50 - 7.60 |
|---|
| 52wk Range: | 5.51 - 10.96 |
|---|
| Volume: | 93,067 |
|---|
| Avg Vol (3m): | 225,053 |
|---|
| Market Cap: | 466.79M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.50 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Nordion Earnings Call Nuggets: Strategic Review and EBIDTA Trendsat Wall St. Cheat Sheet(Fri, Jun 7)
- Nordion Management Discusses Q2 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, Jun 6)
- Stocks to Watch: VeriFone, Ciena, Vera Bradleyat The Wall Street Journal(Thu, Jun 6)
- Nordion to Release Second Quarter 2013 Financial ResultsBusiness Wire(Wed, May 29)
- Nordion upgraded to Buy from Neutral at Sidotitheflyonthewall.com(Thu, May 23)
- Nordion Enters into Agreement to Divest Targeted Therapies Business to BTG plcBusiness Wire(Thu, May 23)
- World Congress on Interventional Oncology to Present Live TheraSphere® AdministrationBusiness Wire(Thu, May 16)
- Nordion signs contract manufacturing agreement with Navideatheflyonthewall.com(Wed, May 15)
- Navidea Biopharmaceuticals Signs Manufacturing and Supply Agreement with NordionBusiness Wire(Wed, May 15)
- Profits Can Be Found In The Expanding And Challenging Medical Isotope Businessat Seeking Alpha(Fri, May 3)
- Nordion to Host Interactive TheraSphere® Educational Session at the SIR Annual Scientific Meeting 2013Business Wire(Wed, Apr 10)
- Nordion to Host European-Based Educational and Scientific Meetings for Liver Cancer SpecialistsBusiness Wire(Tue, Apr 9)
- 3 Radiotherapy Companies That Could Make Big Gains In 2013at Seeking Alpha(Mon, Apr 8)
- Medical Isotope Producers Could Be Lucrative Investment Venturesat Seeking Alpha(Wed, Apr 3)
- Nordion and Dr. Reddy’s Laboratories Settle ClaimsBusiness Wire(Thu, Mar 21)
Key Statistics
| Forward P/E (1 yr): | 12.36 |
|---|
| P/S (ttm): | 1.88 |
|---|
| Ex-Dividend Date: | 14-Jun-12 |
|---|
Analysts
| Annual EPS Est
(Oct-13)
: | 0.52 |
|---|
| Quarterly EPS Est
(Jul-13)
: | 0.17 |
|---|
| Mean Recommendation*: | 2.7 |
|---|
| PEG Ratio (5 yr expected): | 1.61 |
|---|
Business Summary
Nordion Inc. provides products and services for the prevention, diagnosis, and treatment of diseases worldwide. The companys Targeted Therapies segment offers TheraSphere, a therapeutic medical device used in the treatment of inoperable prim...
View More